Pharma Business Line – Tenil Sat, 18 Sep 2021 13:14:48 +0000 en-US hourly 1 Pharma Business Line – Tenil 32 32 OBS Group completes its 6th acquisition in Pakistan Fri, 17 Sep 2021 18:57:40 +0000

OBS Group completes its 6th acquisition in Pakistan. The products acquired belong to different therapeutic classes including anti-infectives + oncology.

MIAMI, FL, USA, September 17, 2021 / – For immediate release
Emilie Bergh

International pharmaceutical news
OBS Group completes its 6th acquisition in Pakistan
The products acquired belong to different therapeutic classes including anti-infectives and oncology.
The Harel Group acted as advisor to OBS

(International distribution) OBS Group, through its subsidiary AGP Limited, listed on the Pakistan Stock Exchange, has completed the acquisition of a portfolio of 22 pharmaceutical products from Sandoz AG. These products were previously marketed in Pakistan under the Sandoz brand. The acquisition of this product portfolio from Sandoz is part of AGP’s commitment to its shareholders to create value through organic and inorganic growth.

AGP’s current presence in the anti-infectives segment will be further strengthened with the acquisition of several Sandoz products in the category. In addition, its oncology division was also strengthened with the addition of acquired oncology products. AGP also plans to introduce new drugs to complement its existing and recently acquired product portfolio from Sandoz.

The products acquired belong to different therapeutic classes including anti-infectives and oncology. Some of the well-established brands that have been acquired include Ternelin and Zatofen, with exclusive licenses granted for the use of Amoxi-Clav, Azomax, and Ospamox in Pakistan in the general drug category, and Paclitaxel and Gemcitabine in the drug segment. ‘oncology.

This transaction was completed for OBS by The Harel Group, a business development advisor in the biopharmaceutical, medical devices, diagnostics and OTC sectors. “The Harel group played an essential role in the closing of this transaction. The group has an excellent network in the global pharmaceutical industry and has delivered on all of its promises, ”said Mr. Tarek Khan, President of the OBS Group.

“We are very proud to contribute to the successful conclusion of the transaction between OBS and Sandoz,” said Jacob Harel, President of the Harel Group. Harel continues: “Both companies are well recognized in the pharmaceutical industry, locally and globally. , and the merger of the two companies will benefit patients and support the business vision of both companies in Pakistan. “

About the OBS group

The OBS group was formed following the acquisition of Organon Pakistan by Mr. Tarek Khan in 2006. The group has grown rapidly over the years and is today one of the leading pharmaceutical groups in Pakistan, ranked among the top 10 local pharmaceutical groups in the country with four manufacturing plants and a national presence.

OBS Group specializes in international partnerships and is known for fostering strategic alliances with reputable international companies whose products touch the lives and well-being of people around the world. The acquisition of Sandoz products is the group’s 6th acquisition since its inception in 2006. Over the years, OBS Group has acquired brands and manufacturing facilities from renowned companies such as Organon, Merck Sharp & Dohme, Schering Plow, AGP, Janssen Pharmaceuticals, and now Sandoz. The group has also entered into partnership agreements with companies such as Mylan, Santen, Vifor and Alliance Pharmaceuticals, among others.

About AGP Limited

AGP Healthcare is one of the most renowned pharmaceutical companies in Pakistan, offering a range of pharmaceuticals in gynecology, pediatrics, internal medicine, cardiology, endocrinology, gastroenterology, ophthalmology, pulmonology, hepatology and oncology.

AGP Healthcare was started as a joint venture between Eli Lilly and Ali Gohar Pharmaceuticals in Pakistan, which was subsequently acquired by OBS Group in 2014. Following the acquisition by OBS Group, the focus was on growth, l efficiency and productivity, which has resulted in significant improvements to business. Over the years, AGP Limited has partnered with many well-known companies including Eli Lilly, Alcon, Mylan, Osmopharm, Dr. Kade, UCB and Alliance Pharmaceuticals.

About the Harel group
The Harel Group is a trusted and well-known business development consultancy with an extensive global network in the biotech / pharmaceutical industry. The group connects pharmaceutical and medical device companies from around the world, facilitating win-win business transactions such as licensing, distribution, acquisitions and divestitures. The Harel Group team is made up of industry professionals with over 200 years of combined experience in the pharmaceutical industry and represents a great cultural diversity. The group is committed to delivering results quickly and efficiently while adhering to ethical business practices.

OBS Group
Muhammad Kamran Mirza, Executive Director
Phone. : + 92-21-111-247-247

The Harel Group
Flora Ma, Senior Consultant
Phone. : +1.908.392.0498

Emily Bergh
R Public relations
+1 518-321-3906
write us here

Editors Note: While The Free Press will always be free to our readers and funded by advertising, we ask our loyal readers to consider a monthly donation of $ 3 to maintain our local journalism and help us grow, as we increase sales. of advertisements locally.

You can click here to support us.

We thank you all for your consideration and for your support of local journalism.

Source link

]]> 0
Supply fears drive European vaccine industry to seek the comforts of home Fri, 17 Sep 2021 07:49:00 +0000 An employee of the pharmaceutical and chemical group Merck KGaA lines up outside a vaccination center at the Merck plant in Darmstadt, Germany on May 4, 2021, as Germany launched projects involving company doctors helping to the state vaccination campaign against coronavirus disease (COVID-19[FEMININE)ArneDedert/PoolviaREUTERS[FEMININE)ArneDedert/PoolviaREUTERS

  • Merck KGaA to diversify geographically to avoid vaccine conflicts
  • Entrepreneur Rentschler wants to source more locally
  • Protectionist moves amid rush for vaccines, “wake-up call”

FRANKFURT, Sept. 17 (Reuters) – European companies playing key supporting roles in COVID-19 vaccine manufacturing are working to bring production and supply chains closer to their customers to guard against restrictions that cut off supplies during the pandemic.

Germany’s Merck KGaA (MRCG.DE), whose Life Science unit is one of the world’s largest manufacturers of bioreactor equipment and supplies, told Reuters it is working to geographically expand its production network so that fewer shipments have to cross customs borders.

U.S. regulations in particular, which prioritize companies performing contracts with the U.S. government, have posed a challenge for Merck as it seeks to meet growing demand for supplies such as sterile fermentation bags and filters.

But the United States is not the only country to engage in what some call vaccine nationalism. India banned vaccine exports in mid-April to focus on its national vaccination campaign as infections exploded across the country, upsetting vaccination plans in many countries in Africa and South Asia . Read more

Following production shortfalls at AstraZeneca (AZN.L) earlier this year, the European Union imposed an export surveillance program and accused Britain of withholding volumes of COVID-19 vaccines which, according to it should be shared with the EU. Read more

“Every forward-looking decision we have taken has incorporated the geographic dimension,” Managing Director Belen Garijo told Reuters. “Against the background of the trade constraints that we have seen, we have increased our global diversification whenever we have had the opportunity,” she added.

At Rentschler Biopharma SE, a German subcontractor for large pharmaceutical companies that is helping produce CureVac’s COVID-19 vaccine candidate (5CV.DE), the pandemic has sparked a review of its supply routes.

“The coronavirus crisis has given us an important boost to bring our supply chains closer to home. We have decided to source most of our equipment from Europe in order to no longer be so dependent on the United States,” a said CEO Frank Mathias, naming sterile bioreactor bags as an example. He would not name the suppliers.

Mathias said supply chains collapsed earlier this year when the United States requisitioned certain volumes for domestic vaccine producers.

The U.S. Defense Production Act, with its listed order system that prioritizes U.S. crisis response, has also hampered Merck’s ability to serve vaccine makers elsewhere in the world.

In response, Merck announced in March its intention to invest € 25 million in France to manufacture disposable plastic materials for bioreactors, a critical input for the manufacture of COVID-19 vaccines.

The new site, Merck’s first such facility in Europe, will likely come on stream at the end of 2021, adding to similar serial production lines in the United States and China. Read more

This followed the $ 47 million investment in its U.S. facilities in Massachusetts and New Hampshire in December, at the time touted as boosting global production to meet unprecedented demand.

“The pandemic has been a wake-up call,” said Garijo of Merck. “You want to have a global footprint so that you can cope with potential business constraints. “

Family-owned Merck also manufactures prescription drugs and chemicals for semiconductor production, but its Life Science unit, primarily made up of companies formerly known as Millipore and Sigma Aldrich, has become its primary revenue engine.

Its competitors are Thermo Fisher (TMO.N), Danaher (DHR.N) and Sartorius (SATG.DE).

In another move to avoid long transport routes and any consequences of international feuds, German family-run vaccine maker IDT Biologika announced earlier this year plans to invest more than € 100 million to produce the COVID-vaccine. 19 from AstraZeneca in collaboration with the Anglo-Swedish drug manufacturer. Read more

The production line, which is currently scheduled to enter service in 2023, is said to be designed to produce Astra vaccines or other vaccines of the same class of viral vectors, at a rate of at least 360 million doses per year. .

IDT would manufacture the active ingredient and mix, bottle and package the final product, combining in one place a series of production steps that are currently widely dispersed.

IDT said the project was on track but declined to comment further. The company said the German Federal Ministry of Health helped with the project but the investment was not subsidized.

Re-equipping production networks in a pharmaceutical sector that has relied for decades on cross-border trade and the international division of labor can only be done in gradual stages, warned Merck CEO Garijo.

“You can’t move a factory overnight, it takes time,” she said.

Reporting by Ludwig Burger and Patricia Weiss; Editing by Hugh Lawson

Our standards: Thomson Reuters Trust Principles.

Source link

]]> 0
Profit Outlook of ECS Botanics Holdings Ltd (ASX: ECS) Thu, 16 Sep 2021 20:50:31 +0000

ECS Botanics Holdings Ltd (ASX: ECS) Perhaps a major achievement in his business is approaching, so we would like to shed some light on the business. ECS Botanics Holdings Ltd, a hemp-based food and food company, grows and processes industrial hemp in Australia. The A $ 39 million market-capitalization company reported a final loss of A $ 4.3 million on June 30, 2021 for its latest result for the year. The most pressing concern for investors is the path to profitability of ECS Botanics Holdings – when will it break even? Below, we’ll provide a high-level summary of industry analyst expectations for the company.

See our latest review for ECS Botanics Holdings

ECS Botanics Holdings is close to equilibrium, according to some analysts at Australian Pharmaceuticals. They expect the company to make a terminal loss in 2023, before making a profit of AU $ 3.2 million in 2024. Therefore, the company is expected to break even in about 3 years. How fast will the company have to grow from one year to the next to reach equilibrium on that date? Using a line of best fit, we calculated an average annual growth rate of 104%, which is pretty optimistic! If the business grows at a slower pace, it will become profitable later than expected.

ASX Earnings Per Share Growth: ECS September 16, 2021

Since this is a high-level overview, we will not go into details of upcoming projects for ECS Botanics Holdings. However, keep in mind that in general, a pharmaceutical company has irregular cash flows which depend on the drug and the stage of development of the product. Business is on the move. Thus, a high growth rate is not unusual, especially when a company is in the period of investment.

One thing we would like to point out is that the company has managed its capital prudently, with debt representing 0.008% of equity. This means that it has primarily funded its operations from equity and its low debt reduces the risk of investing in the loss-making company.

Next steps:

There are some fundamentals of ECS Botanics Holdings that are not covered in this article, but we must again stress that this is only a basic overview. For a more complete overview of ECS Botanics Holdings, see the ECS Botanics Holdings company page on Simply Wall St. We have also put together a list of relevant factors you should consider further:

  1. Historical review: How has ECS Botanics Holdings performed in the past? Go deeper into the background analysis and take a look at the free visual representations of our analysis for clarity.
  2. Management team: An experienced management team at the helm increases our confidence in the company – look at who sits on the board of directors of ECS Botanics Holdings and the CEO’s background.
  3. Other high performing stocks: Are there other stocks that offer better prospects with a proven track record? Explore our free list of these great stocks here.

When trading ECS ​​Botanics Holdings or any other investment, use the platform seen by many as the professionals’ gateway to the global market, Interactive brokers. You get the cheapest * trading on stocks, options, futures, forex, bonds and funds from around the world from a single integrated account. Promoted

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative material. Simply Wall St has no position in any of the stocks mentioned.
*Interactive Brokers Ranked Least Expensive Broker By Online Annual Review 2020

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at)

Source link

]]> 0
Pharmaceutical Plant To Add 290 More Jobs With Expansion | Local News Wed, 15 Sep 2021 07:45:00 +0000

Pitt County’s economy will see 290 new jobs and an investment of $ 154 million thanks to another expansion of Thermo Fisher Scientific, Governor Roy Cooper and local leaders said Tuesday.

The expansion of the company’s pharmaceutical manufacturing operations in Greenville comes in addition to a $ 500 million project announced in December 2020 that was expected to create 500 jobs. Brad Hufford, vice president of business development for the Greenville ENC Alliance, said the new expansion would result in an annual increase of $ 19.2 million in the region’s annual payroll.

“These are just salaries,” Hufford said. “It is not even the tax base that will be increased with this investment. These paychecks that the workers will receive are having a huge ripple effect in the communities of the region. “

The project will expand the company’s sterile production capabilities, providing more space for sterile liquids and freeze-dried pharmaceuticals, Hufford said. A continuous manufacturing suite will also be added on the oral-solid production side. The expansion will partially use a new 130,000 square foot facility on the Greenville campus, allowing new employees to fill a variety of roles.

“When the company makes such a big investment, it’s not just the front-line operators on the line, but a ton of support staff as well who make this work work,” Hufford said. “You will also see factory supervisors and roles for packaging as well as material handling. Not all of these jobs will require graduate degrees. There will be plenty of jobs for those who are graduating from high school or taking training at one of our community colleges.

The state Department of Commerce has led efforts to support the expansion, a statement from the governor’s office said Tuesday, and annual salaries are expected to be 50% higher than the county’s overall annual salary of $ 42,801. Pitt.

“The continued growth in the capabilities and capabilities of our Greenville site has enabled us to meet the needs of our customers and the patients they serve,” said Michel Lagarde, executive vice president of Thermo Fisher Scientific. “This new investment will enable new capacities for innovation and development to meet the accelerated demand for critical drugs and therapies. We also look forward to continued job creation and economic development in this region.

The company employs people from more than 25 counties, according to Hufford. Its Greenville site provides both manufacturing and packaging services for sterile and oral pharmaceuticals from initial development through commercial phase. As one of Thermo Fisher Scientific’s largest sites and the largest industrial employer in Pitt County, the Greenville campus currently employs approximately 1,800 and occupies 1.5 million square feet on 142 acres.

The state’s economic investment committee on Tuesday morning approved a 12-year Employment Development Investment Grant (JDIG) under the project, which will authorize up to $ 4.5 million in reimbursement to the company over 12 years. The JDIG will require the company to meet the goals of job creation and additional investment, as reviewed by the Departments of Commerce and Revenue.

Economists from the Department of Commerce estimate that the project will grow the state’s economy by more than $ 977 million over the same period.

The process was competitive. Hufford said Thermo Fisher Scientific has examined their locations around the world to determine where an investment could be made. Mayor PJ Connelly, in a Greenville ENC Alliance statement on Tuesday, said Greenville’s victory was indicative of the city’s economic condition.

“After competing globally, our community has come out on top because we have the workforce, the business climate and the resources to meet their growth needs. “

Cooper said the announcement speaks to the state’s reputation as a hub for the life sciences industry.

“With our skilled workforce, strong collaboration with industry and an innovative business climate, this decision proves, once again, that North Carolina’s biotech industry is thriving statewide. “Cooper said.

“The strength of our life sciences industry is evident through Thermo Fisher’s increased investment in eastern North Carolina,” said Secretary of State for Commerce Machelle Baker Sanders. “North Carolina is home to a diverse life sciences workforce and world-class universities and community colleges, which develop the nation’s best and brightest talent. We will continue to help growing innovators improve the lives of North Carolinians and our global community for generations to come. “

About $ 503,000 of JDIG will go to the Industrial Development Fund-State Utilities Account, which helps rural communities finance infrastructure upgrades needed to attract future businesses.

Pitt County state lawmakers see the investment as a way to continue to establish the region’s footprint in life sciences, especially the ‘biopharmaceuticals growing’ of Pitt, Edgecombe, Wilson, Counties. Johnston and Nash.

“These additional, well-paying jobs are welcome news for our community,” said State Senator Don Davis. “North Carolina’s pharmaceutical manufacturing workforce is the third largest in the country, and I can assure you that eastern North Carolina has the talent to support the company’s future innovation. . “

“Our region is experiencing strong growth in the life sciences and that is thanks to multi-million dollar investments from companies like Thermo Fisher,” said State Representative Brian Farkas. “We are committed to partnering with Thermo Fisher, locally and state level, as they embark on this exciting new phase of growth and continue to make Pitt County their home. “

The region’s higher education institutions, Pitt Community College and East Carolina University, acted as key partners in the project. Hufford said the success of ECU and PCC, as well as their talent pool, are major strengths. He said higher education institutions’ commitment to growth was visible in ECU’s new Center for Life Sciences and Biotechnology, a $ 90 million investment from the university, which is expected to be completed on October 18.

Other key project partners include the North Carolina General Assembly, State Community College System, North Carolina Biotechnology Center, Pitt County, Pitt County Economic Development, City of Greenville, Greenville ENC Alliance and Greenville Utilities.

The City of Greenville, the Greenville ENC Alliance and the NC Biotechnology Center will also provide grants in support of Thermo Fisher’s latest expansion.

“As Thermo Fisher grows, Pitt County grows,” said Kelly Andrews, economic development manager for Pitt County. “We are working with Thermo Fisher and many partners to improve our biopharmaceutical support network, which has grown over decades and is unique in this region. “

Source link

]]> 0
Chutes & Ladders — Former FDA Commissioner Hahn Assumes Interim Marketing Director Role at YourBio Health Fri, 10 Sep 2021 13:30:00 +0000

Welcome to this week’s Chutes & Ladders, our roundup of hires, layoffs and retirements across the industry. Please send your store’s good or bad word to Kyle LaHucik, and we’ll feature it here at the end of each week.

Former FDA Commissioner Hahn Joins Flagship Incubated YourBio Health as Interim Marketing Director

YourBio Health
Stephen hahn, MD, will be the Interim Chief Medical Officer of YourBio Health.

The former FDA commissioner, who cleared the emergency use of COVID-19 vaccines last year, will be the acting marketing director of the incubated flagship COVID-19 diagnostic and blood collection company. Formerly known as Seventh Sense Biosystems, the company was founded in 2011 and offers post-vaccine antibody tests for COVID-19 that can be used after a stroke from Moderna, another flagship company. Hahn joined the Flagship life sciences incubator earlier this summer. Fierce MedTech

Glympse Bio Selects Gilead Liver Disease Leader As First Chief Medical Officer

Glympe Bio
Tram, MD, will be Glympse Bio’s first chief medical officer.

After leading the Global Liver Disease Unit for Gilead Sciences, Tran will oversee injectable biosensor technology at Glympse. Tran will help advance the technology throughout clinical development and through the finish line of FDA approval. She specializes in liver and viruses. The main indication of Glympse for biosensors is the detection of non-alcoholic steatohepatitis, fatty liver disease commonly known as NASH. Fierce MedTech

Orchard Therapeutics Takes Novartis Cell and Gene Leader Smart Immune CSO and Promotes CMO

Orchard therapy
Nicoletta Loggia, Ph.D., is leaving Novartis to become CTO of Orchard.

Loggia headed the global cell and gene therapy unit at Novartis and was a 17-year veteran of Swiss Big Pharma. She is reprising the role of Ran Zheng, who left for Landmark Bio in July.

Loggia is joined by a new Scientific Director Fulvio Mavilio, Ph.D., who held the same position at Smart Immune. He was previously senior vice president of translational science at Audentes Therapeutics. The orchard also promoted Leslie Meltzer, Ph.D., to the Chief Medical Officer. She joined Orchard in 2018 after previously working in medical affairs at Keryx and Biogen. Fierce biotech

> Hiring of decentralized clinical trials software company Medable MaryAnne Rizk, Ph.D., as Director of Strategy. Rizk is the seventh executive to join the company this year and comes from senior positions at Oracle and Medidata Solutions. Fierce biotech

> XNK Therapeutics selected Markus Thor as a business leader. He joined clinical stage immunotherapy biotechnology at North Venture Partners, where he was a Managing Partner. Exit

> Immunitas Therapeutics appointed Seng-Lai “Thomas” Tan, Ph.D., as Scientific Director. Tan joined Bicara Therapeutics’ single-cell genomics biotechnology, where he was also CSO. Exit

> Elizabeth Eagling-Vose will be senior vice president of operations at Enesi Pharma. She joins Vaccitech’s Next Generation Vaccine Biotechnology, where Eagling-Vose was Senior Director and Head of Clinical Operations. Exit

> Seelos Therapeutics promoted Michel Golembiewski to the financial director and Antoine Marciano to the communications manager. Golembiewski joined as Vice President of Finance in January 2019, and Marciano joined as Head of Corporate Communications in January 2019. Exit

> Genezen cell and gene therapy contract development and manufacturing organization named Ray kaczmarek as CEO. Kaczmarek comes from TriLink Biotechnologies, where he was senior vice president of GMP operations. Exit

> Discovery Life Sciences made two executive appointments this week: Shawn levy, Ph.D., to the Scientific Director, and Mike Musgnug as Director of Revenue. Levy joined the specialist in biological samples and biomarkers in 2019, and Musgnug was previously vice president and general manager of the biotechnology unit at Beckman Coulter Life Sciences. Exit and Exit

> Jay Saoud retires from Minerva Neurosciences. Ramana kuchibhatla, Ph.D., will replace him as senior vice president and head of research and development. Kuchibhatla comes from PRA Health Sciences, where he was executive director of global drug development. Exit

> Isabelle Carmona will be the director of human resources for Rocket Pharmaceuticals. Carmona joins Ichnos Sciences’ Rare Childhood Disorders Clinical Stage Biotechnology, where she held the same title. Exit

> Tom stocky becomes vice president of product for machine learning drug discovery and development company insitro. Stocky was previously a technology researcher at Denali Therapeutics and before that, vice president of research and profile at Facebook. Exit

> Protagonist Therapeutics appointed Scott Plevy, MD, is Executive Vice President and Therapeutic Lead of Gastroenterology. Plevy joined biopharma from Senda Biosciences, where he was Scientific Director. Exit

> The new CFO of LocanaBio is Kat Lange. Lange joins JP Morgan’s RNA gene therapy biotechnology, where she was executive director of the healthcare investment banking group. Exit

> Patrick j fowler becomes Senior Vice President of Business Development and Strategy at Vericel, a sports medicine and severe burns company. Fowler is from Sanofi, where he was responsible for the North American strategy for operations and new product development. Exit

> X4 Pharmaceuticals promoted Marie DiBiase, Ph.D., to become its first COO. DiBiase joined Immune System Biotechnology in 2017 after serving as Vice President of Technical Operations at Epirus Biopharmaceuticals. Exit

> Marc Blaustein will be the Chief Operating Officer of Clinical-Stage Microbiome Biotechnology Finch Therapeutics. Blaustein was previously responsible for the business development of Guide Therapeutics, acquired by Beam Therapeutics this year, and prior to that he was CEO of NED Biosystems and Akashi Therapeutics. Exit

> Eloxx Pharmaceuticals selected Ali Hariri, MD, as Chief Medical Officer. He joined Rare Disease Biotechnology from Sanofi, where he was senior global project manager for rare disease clinical development. Exit

> Intrommune Therapeutics appointed Stuart loesch commercial director. Loesch joined clinical stage food allergy biotechnology from ALK, where he was vice president of marketing and business strategy for North America. Exit

> LightDeck Diagnostics has chosen Russ Peloquin as new sales manager and Franck Gill as a product manager. Peloquin joined SQI Diagnostics, where he was vice president of global business operations. Gill joined LightDeck in August 2020 as VP of Manufacturing after serving as VP of Operations at iCarbonX. Exit

> Flamingo Therapeutics named RNA therapy biotechnology Rob MacLeod, Ph.D., its scientific director as part of a collaboration with Ionis. MacLeod is currently Vice President of Oncology Research and Development at Ionis. Exit

> Eric Groen joins Rani Therapeutics as General Counsel. Groen comes to Amgen’s clinical stage biotech, where he spent nearly 20 years, including most recently as Regional General Counsel for Amgen’s business operations in Canada, Latin America, the Middle East and Africa. Exit

> Jonathan I. Lieber is the new CFO of Applied Genetic Technologies. Lieber joins Gene Therapy Biotech from Danforth Advisors, where he was Managing Director. Exit

> Aquarius named Therapeutics Karen tubridy as director of development. Tubridy joined Akebia Therapeutics, where she was Senior Vice President of Global Programs and Director of Development. Exit

> Tim smith will be Senior Vice President and Head of Business Development at PMV Pharmaceuticals. He joined the precision oncology company of Aquarius Therapeutics, where he was commercial director. Exit

> Neoleukin Therapeutics appointed Bill arthur, Ph.D., its vice-president and director of research. Arthur previously spent a decade at Seagen, most recently as Senior Director and Head of Cancer Biology. Exit

> Frank J. Hsu, MD, is Apeexigen’s new chief medical officer. Hsu joins Oncternal Therapeutics’ oncology antibody biopharmacy, where he held the same role. Exit

> Zoran Zdraveski, Ph.D., is now the legal director of the biopharmaceutical company TScan Therapeutics on cell therapies. Zdraveski was previously Director of Legal and Technology Operations at Magenta Therapeutics. Exit

> Biotech Biophytis on age-related diseases at the named clinical stage Rob van maanen, MD, his chief medical officer. He was previously CMO at Dutch biotechnology Khondrion and before that Senior Medical Director at Astellas. Exit

Source link

]]> 0
Sitics Logistic Solutions acquires Udgam Logistics Wed, 08 Sep 2021 05:28:51 +0000

Sitics Logistic Solutions Private Limited, a technology-based supply chain company based in Palakkad, has acquired Udgam Logistics, a Delhi-based cold chain and distribution start-up, for an undisclosed amount.

This is the second acquisition of Sitics Logistic Solutions, which had acquired, three months ago, Quifers, an innovative technology startup in logistics.

The latest acquisition of Udgam Logistics has propelled Sitics into the global 3PL market value chain to reach new heights. While it places Sitics as one of the only integrated supply chain service providers, it also enters the $ 25 billion cold chain market. Udgam’s market positioning with its cutting-edge temperature-controlled solutions will expand Sitics’ footprint and help it access new markets, not to mention a significant increase in turnover. The combination would open up huge cross-sell and up-sell opportunities for the two companies as a combined entity.

Backwater Capital, a Kochi-based investment advisory firm, acted as advisor to the transaction.

Sikander AM – Founder and CEO, Sitics Logistic Solutions Pvt Ltd said that “this acquisition will help target a new segment and deliver tremendous value to customers. Sectors such as Pharmaceuticals, Fast Food, HORECA, Agriculture, Dairy and Marine are growing rapidly and need a world-class temperature-controlled supply chain that we will be able to to provide thanks to the expertise, experience and processes of Udgam. Combined with our technology platform, it has enabled us to offer unique cutting-edge solutions that will build a market-leading presence in the segment. ”

Rahul Mathur, Founder and Director of Udgam Logistics, said the merger would allow it to emerge as an integrated player with a wide reach, offering unique and innovative solutions in the field of logistics, especially with regard to temperature-controlled supply chains. Sitics’ presence and expertise in logistics technologies, e-commerce, warehousing, C&F operations spanning South East Asia, Europe, Australia and the United States provide ample opportunities for develop this vertical with cutting-edge and technology-driven solutions resulting in superior service and quality to customers, both nationally and globally.


Source link

]]> 0
Dr. Reddy’s Labs signs with Citius Pharmaceuticals Sat, 04 Sep 2021 05:57:06 +0000

Dr. Reddy’s Laboratories announced that it has entered into a definitive agreement with Citius Pharmaceuticals under which it has sold all of its rights to E7777 (a modified diphtheria toxin IL-2 fusion protein) and certain related assets.

Under the terms of the deal, Dr. Reddy’s will receive $ 40 million upon closing, followed by an approval milestone payment of up to $ 40 million related to the approval of the CTCL indication. (cutaneous T lymphoma) and up to $ 70 million for additional indication approvals. In addition, Dr. Reddy’s will receive certain sales-based milestones and installment top-up payments.

Also see: Natco Pharma branch launches lenalidomide in Canada

In March 2016, Dr. Reddy’s acquired the exclusive worldwide rights (excluding Japan and Asia) to the investigational cancer agent E7777 from Eisai Co. Ltd.

Erez Israel, CEO of Dr Reddy’s, said in a statement, “Addressing the unmet needs of oncology patients remains a priority area for us. E7777 has significant potential as an important component of systemic therapy for CTCL and other cancers. After the acquisition of Eisai, significant progress was made on the development front of CTCL. We are confident in Citius’ ability to realize the full potential of E7777 in the treatment of CTCL as well as in its ability to develop this promising drug for other indications in oncology and immuno-oncology ”.

Source link

]]> 0
GMR Hyderabad Air Cargo partners with DoKaSch Wed, 01 Sep 2021 09:23:01 +0000

GMR Hyderabad Air Cargo (GHAC), a division of GMR Air Cargo and Aerospace Engineering Limited, has partnered with DoKaSch Temperature Solutions of Germany to launch a dedicated service station for temperature-controlled air cargo containers Opticooler.

It became the first and only Indian node in DoKaSch Temperature Solutions’ global network of service stations.

GMR Hyderabad Air Cargo becomes first terminal to handle Nexgen Envirotainer Releye RLP containers

With its dedicated pharmaceutical export terminal named “Pharma Zone”, the GHAC facility in Hyderabad is a privileged hub for pharmaceutical exports in south-central India and the positioning of containers at the network station. Hyderabad provides local pharmaceutical manufacturers, freight forwarders and global transportation companies with high-value life-saving drugs. These are essential for the Hyderabad-based Covid-19 vaccine manufacturers.

Serve as a regional hub

Pradeep Panicker, CEO of GMR Hyderabad International Airport, said: “The Hyderabad Air Cargo Terminal is the preferred gateway for the movement of pharmaceuticals and vaccines in the South Asian region and we have partnered with DoKaSch Temperature Solutions to establish a service station in our freight terminal.

“With the addition of this facility, GMR Hyderabad Air Cargo will be the largest hub for temperature-controlled air cargo containers in the region. “

Air freight is growing steadily, inches from pre-Covid levels

Andreas Seitz, Managing Director of DoKaSch Temperature Solutions, said: “India is a very relevant location for pharmaceuticals, biosimilars and biotechnology and, in particular, Hyderabad is of exceptional importance. In turn, we have decided to open our new service station to complete our vast network and contribute to an efficient cold chain for these products. Not only is the station located in an industrial hub of global importance, the airport is also used by many of our partner airlines and is well connected to destinations around the world.

The new gas station operated by GHAC on behalf of DoKaSch will be able to accommodate up to 100 specialized temperature-controlled containers at a time and will serve as a regional hub for DoKaSch customers.

Source link

]]> 0
Fosun Pharma Reports 45% Profit Increase on Strong Sales of Cancer Drugs Sat, 28 Aug 2021 04:40:00 +0000

China’s leading drug developer, Shanghai Fosun Pharmaceutical Group Co. Ltd., reported a 45% increase in first-half profits on strong sales of its cancer treatments and anti-infective drugs, as it s ” is working to obtain authorization to market a key Covid-19 developed abroad. vaccine in China.

Net profit attributable to shareholders was 2.48 billion yuan ($ 383 million) in the first half, with revenue increasing 21% to 16.52 billion yuan, supported by more than a three-fold increase in sales about her cancer treatments, which included her injection of rituximab used to treat non-Hodgkin lymphoma, according to A declaration published Tuesday on the Hong Kong Stock Exchange.

Sales of drugs used to fight infections increased 45%, with these two categories of therapeutic products contributing the most to the sales of the company’s drug portfolio. Revenue from regions outside of mainland China also contributed to the company’s bottom line, gaining 28% and accounting for nearly a third of total revenue as it sought to boost its operations. business abroad.

Pharmaceutical drugs contributed about 12.25 billion yuan to the company’s coffers in the first half, accounting for more than 72% of its revenue. This was compared to a 7.4% growth for medical devices and diagnostics.

Sales in Hong Kong and Macao of the Comirnaty Covid-19 vaccine, made with technology invented by Germany’s BioNTech and developed and marketed elsewhere in the world by US drug giant Pfizer, contributed 500 million yuan to sales of Fosun, as approval of its use in China the mainland languishes with regulators.

Fosun and BioNTech formed a $ 200 million joint venture in May to manufacture up to 1 billion doses of the vaccine in China once approved for use. Fosun is BioNTech’s exclusive partner to market the drug in Hong Kong, Macao and Taiwan.

Fosun also plans to eventually deliver 15 million doses of mRNA vaccine to Taiwan, according to the findings report.

This effort received a boost this week after US regulators fully approved the messenger RNA (mRNA) vaccine for people aged 16 and older, after previously clearing its widespread use in a program. emergency authorization.

Despite its proven success in preventing people from becoming seriously ill and requiring hospitalization, Comirnaty has yet to receive a clear timeline for approval in China, sources familiar with the effort told Caixin.

This is despite the fact that Fosun Pharma chairman and CEO Wu Yifang said in June that local vaccine production lines were due to start operating in August.

Wu was more cautious in a call to investors on Wednesday, only reiterating that national Phase II clinical trials were underway and the regulatory process “is proceeding smoothly.”

Wu said the U.S. approval shows the FDA’s confidence in the technology and quality of the vaccine, and evidence of that approval would be turned over to regulatory authorities in Hong Kong and Macao where the vaccine is used.

These Phase II clinical trials, conducted in Jiangsu, tested a double-dose regimen similar to that used in the United States, according to a plan published on and last updated in February.

In July, Caixin reported that regulators were considering authorizing the use of BioNTech’s vaccine as a one-time booster for people who have previously been doubly vaccinated with an inactivated virus vaccine, such as those manufactured by the national companies Sinovac and Sinopharm.

Fosun Pharma did not respond to Caixin’s questions, but said the approval process for Comirnaty “was proceeding normally according to procedures”.

“The clinical trials and approval of the Covid-19 mRNA vaccine in China have been supported and supported by several departments, including the Joint Prevention and Control Mechanism, the National Administration of Medical Products, the Municipal Committee of Shanghai CCP and the Shanghai government, ”Guo said. Guangchang, the chairman and majority shareholder of Fosun Pharma, in a statement to Caixin.

Comirnaty works by providing genetic instructions to make the virus spike protein inside healthy cells, which stimulates an immune response. MRNA injections have higher efficiency rates that vaccines from domestic manufacturers, including those from Sinovac Biotech Ltd. and Sinopharm Group Co.

More than a billion doses of Comirnaty had been delivered to more than 100 countries or territories around the world as of July, according to BioNTech.

“Fosun’s original intention in developing the Covid-19 mRNA vaccine was to proceed in accordance with the national interest and give the country a choice,” Guo said during an investor appeal Thursday.

As those in China concerned about future delta outbreaks and the effectiveness of local vaccines closely monitor a regulatory green light, Commirnaty is currently a small part of the business of Fosun Pharma.

The company wanted to highlight its investment in innovative R&D in the first half results, touting spending of around 1.5 billion yuan in areas such as innovative anticancer drugs.

In June, the Chinese medical regulator gave the green light to Fosun Pharma Kite Biotechnology Co. Ltd., a joint venture of Fosun Pharma and a unit of US pharmaceutical giant Gilead Sciences Inc., to begin marketing Gilead’s Yescarta as a treatment of last. remedies for certain types of blood cancer.

The approval represented the jurisdiction’s first CAR-T cell therapy, an advanced cancer treatment where doctors train a patient’s own immune cells to fight disease.

Contact reporter Flynn Murphy ( and editor-in-chief Michael Bellart (

To download our app for getting late-breaking alerts and reading news on the go.

To have our free weekly newsletter must read.

You have accessed an article available only to subscribers


Source link

]]> 0
What happens to a Fortune 500’s 2025 playbook if the Chinese market is not one of them? Tue, 24 Aug 2021 14:49:52 +0000

William C. Kirby: In my decades of engagement with China, I have seen how the country can change in no time. Politics can undermine business strategies overnight. Yet China is only gaining in importance to the global economy, and so it’s no surprise that business leaders with interests in China are considering many different scenarios.

Pharmaceutical executives would be wise to align themselves with the Chinese government’s goal of moving from mass manufacturing to high-quality manufacturing. This is the best way to compete with the growing number of skilled Chinese entrants in the industry. Foreign companies need to make sure they understand this changing landscape. To do this, they should use China’s growing talent pool. Chinese investments in human capital are among the most important for the future of the country. Young Chinese are world class in their abilities. At Harvard, Chinese students make up the largest part of our international student body. Calling on emerging leaders like these, who know China and its relations with the world so well, would position these companies for success in China, regardless of its political trajectory.

Given that the readers of this Q&A series come from various positions within biopharmaceutical companies, what are your top three recommendations as they strive to successfully engage in the Chinese market?

The history of modern China shows how deeply the country’s development is shaped by its foreign relations. The closer China’s ties to the world, the greater the possibilities for its development. Isolating China, especially during difficult times like this, may seem like the easy prescription, but it’s not safe. I recommend other approaches:

First, recognize the innovation that is happening in China today. In the early 2000s and before, the Fortune 500 commissioned expatriates to lead their operations in China to share best practices from the United States and Europe. The times have changed. Companies like Taikang Insurance Company developed a cradle-to-paradise customer development model that international companies could only hope to replicate. For example, the company had accumulated over 80,000 high net worth clients in just under six years, and then the number began to grow by over 20,000 per year.2 Their success is tied to an intimate understanding of China today.

Second, remember that local innovation can now overtake even the best-run international companies. In 2000, Yunnan Baiyao sold approximately $ 12,000 worth of medicated adhesive plasters. Until then, J&J, which recently made the top twenty on the Fortune list of the world’s most admired companies for 2021 while also ranking # 1 in the pharmaceutical category for the eighth consecutive year, was the dominant leader. of the market. Yet by combining bandages with their medicinal formula, Yunnan Baiyao Adhesive Bandages achieved 40% market share in 2007; exceeding J & J’s who had contracted at just 30%.3

Finally, change your mind about how your business success in China affects you. Even if you are located outside of China and working in an area that is not directly related to the progress of your business in China, imagine what could happen if the growth of that particular business unit slows down. When executives need to meet their overall sales forecast, will they accept lower expected revenue? or will other units, like yours, be called upon to step up and consolidate the sales target? There are many ways to align your business with China’s developments and social challenges. Take the case of China’s aging population and minimal health care safety nets. The private sector has an important role to play in finding solutions to these problems. For example, while care for the elderly was first introduced in the early 2000s, the industry has grown at breakneck speed. How might your team evolve to meet the needs of an increasingly educated Chinese consumer market in healthcare? As China changes, so must your business.

William C. Kirby is Spangler Family Professor of Business Administration at Harvard Business School and TM Chang Professor of China Studies at Harvard University. Professor Kirby is chairman of the Harvard China Fund, the university’s university venture capital fund for China, and faculty chairman of Harvard Center Shanghai, Harvard’s first university center outside the United States.

Michael Wong is an Emeritus Board Member of the Harvard Business School Healthcare Alumni Association.


1. For 2020, China’s sales contribution as a percentage of total sales was 20.2% for AstraZeneca, 7.7% for Merck and 6.0% for Pfizer.

2. Kirby, William C., Lin, Shu, McHugh, John P., Wang, Yuanzhou, From cradle to paradise: Taikang Insurance Group, Harvard Business School, March 6, 2020.

3. Chu, Michael, Kirby, William C., Dai, Nancy Hua, Wang, Yuanzhou, Yunnan Baiyao: Transforming a Chinese State-Company owned, Harvard Business School, April 3, 2018.

Source link

]]> 0